Interview with Eric Zwisler, President, Cardinal Health China
We last met with you as the head of Zuellig in 2009. Obviously, a lot has changed since then; from both a sector and corporate point of view, what have…
Address: Corporate Office
Ocean Building, 15/F
550 Yanan East Road
Shanghai, China 200001,China
Tel: +86 21.5306.0001
Web: http://www.cardinal.com/us/en/CN/EN
Cardinal Health is a dynamic and publicly listed top 50 global company specializing in healthcare services and wholesale distribution. Founded in 1971, Cardinal Health has become a leader in the healthcare services sector. The company serves more than 60,000 healthcare sites daily and has over 50,000 customers in North America. One-third of all distributed pharmaceutical, laboratory and medical products in the U.S. and Puerto Rico flow through the Cardinal Health supply chain.
Consumer Healthcare, Direct To Patient (DTP), Channel Management Intelligence, Logistics, Medical devices
We last met with you as the head of Zuellig in 2009. Obviously, a lot has changed since then; from both a sector and corporate point of view, what have…
Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself…
Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from…
2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been…
Regular PharmaBoardroom contributor David Crean looks at how the ongoing global coronavirus outbreak has impacted the global economy, how the biopharmaceutical industry is responding, and what the longer-term consequences of…
Bing Xu, GM of Vital River Laboratories, shares the company’s development in the last 20 years; the challenges of advantages of their JV with Charles River Laboratories; the importance of…
This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of the tremendous gains the Chinese healthcare industry made in 2019 while simultaneously…
Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to…
Researchers at the Institut Pasteur in Paris have become the first in Europe to fully sequence the genome of the 2019-nCoV coronavirus – putting the Institut at the forefront of…
The Chinese healthcare market has transformed dramatically in the past few years. There have been many reforms centred around the country’s vision of becoming a healthcare technology powerhouse in the…
Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in China and the US, his motivation to establish…
2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland…
Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, shares his perspectives on the growth of China’s Life Sciences and Healthcare market, the strong presence of Deloitte…
See our Cookie Privacy Policy Here